Eilean Therapeutics

Oct 29, 2024

EILEAN THERAPEUTICS ANNOUNCES UPCOMING PRESENTATION OF A FIRST-IN-CLASS MALT1 DEGRADER AT ASH ANNUAL MEETING

Oct 15, 2024

LOMOND THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR PHASE 1 STUDY OF LONITOCLAX, A SELECTIVE BCL2 INHIBITOR, FOR CHRONIC LYMPHOCYTIC LEUKEMIA, SMALL LYMPHOCYTIC LYMPHOMA, AND SELECT LOW-GRADE LYMPHOMAS

Jun 11, 2024

Eilean Therapeutics Joins The Leukemia & Lymphoma Society's Groundbreaking Beat AML® Master Clinical Trial

Mar 11, 2024

EILEAN THERAPEUTICS APPROVED TO INITIATE FIRST PATIENT TRIAL WITH BALAMENIB (ZE63-0302), A SELECTIVE BEST-IN-CLASS MENIN INHIBITOR

Mar 04, 2024

EILEAN THERAPEUTICS ACQUIRES BEST-IN-CLASS NON-CLINICAL PTPN2 PROGRAM

Jan 29, 2024

EILEAN THERAPEUTICS INITIATES FIRST IN HUMAN TRIAL WITH EILETOCLAX, A SELECTIVE BCL2 INHIBITOR WITH LIMITED IMMUNE SUPPRESSION AND IMPROVED SAFETY COMPARED TO VENETOCLAX AND VENETOCLAX-LIKE MOLECULES